Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It has been quiet for a while in terms of press releases. But note the spike in volume this week. It means something is up. There will be info put our soon. Perhaps a new product, new distribution deal, upward spike in sales, etc. Volume has preceded announcements in the recent past. As happens with many of these small caps, people involved in negotiations with the CEO talk to their friends. Waych for good news and a continuation of the price rise.
IMMD is being positioned as a developer and marketer of innovative health products for a diverse array of widespread medical conditions. If they can execute the sales task, the company will be a new powerhouse in the alternative medicine arena. Huge!
VERY POSITIVE MOVE AND ANNOUNCEMENT that will accelerate company growth by expanding into additional channels. Cancer Treatment centers of America connection is spectacular.
MT. KISCO, N.Y., June 01, 2016 (GLOBE NEWSWIRE) -- ImmuDyne(IMMD) announced today the appointment of Messrs. Adam Lefton and Michael Levin to a newly-formed advisory board formed to explore further commercialization opportunities for the Company's proprietary oral beta-glucan products.
Adam Lefton previously served as Chief Marketing Officer for Nobilis Health Corp.(HLTH) (f/k/a Northstar Healthcare Inc.), an ambulatory surgical center group. Prior to Nobilis, Mr. Lefton was Vice President of Brand Strategy at Cancer Treatment Centers of America (CTCA), where he helped build one of the most successful hospital-based direct to consumer marketing programs in the United States.
Michael D. Levin has over 40 years of healthcare industry experience and expertise in business development and regulatory affairs having served as President at Bergstrom Nutrition (f/k/a Cardinal Nutrition), a leading global supplier of GRAS dietary ingredients, VP at Baxter Healthcare and an advisory board member at the dietary supplement subsidiary of Cancer Treatment Centers of America.
"We have long held the belief that our beta-glucan is an effective solution to large unmet needs in healthcare. We have appointed two highly-experienced executives to spearhead an advisory board that will be tasked with developing a strategy to address these needs with our solutions," stated Mark McLaughlin, CEO and President of ImmuDyne(IMMD).
MT. KISCO, N.Y., Dec. 10, 2015 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) today announced that it has engaged One Equity Research LLC ("One Equity") to provide advisory services and research covering milestone or inflection points in the Company's development.
One Equity has built a robust network that enables them to reach tens of thousands of highly-targeted investors with a high-affinity for undervalued growth companies. ImmuDyne believes this visibility will benefit the Company's growth and vision for the future.
So where are the "tens of thousands" of "investors with a high-affinity for undervalued growth companies."?
Is this another McLaughlin debacle? IMMD has great products, with the most potent patented processes, in a market that is growing. Yet, he fails to deliver. There is no evidence of increased investor interest and the stock price is stuck. Get the I.R. program going or get someone who can!
Kudos to Dan Byrnes! He obviously is behind these moves. With the board changes, Dan is now in control and Scot is rightly sidelined to a P.R. role in Canada. Further, with honest adults now in charge, Dan and Otto will be able to secure financing/JV partners, etc. to move SRSR forward. I expect things will accelerate in next few months. We owe dan aplause.
Very good research. I agree with your points and I hope IMMD management takes your advice immediately. Perhaps you should call McLaughlin. His number is on the website and maybe even on iHub.
Ramping up sales of a relatively new (in terms of marketing effort) retail/personal product is a costly process. The U.S health and beauty market is an immense market with numerous competing products that create a cacophony of competing messages. Cutting through all the noise and convincing customers to buy your offering requires potent tactics and frequent repetition. (as a way of validating my comments, I had a career in marketing and taught it at Temple U.)
What I am most impressed by is the rapid movement to correct initial missteps. IMO McLaughlin, being a novice in consumer marketing attempted to minimize costs by contracting his customer service operation, with sub-par results. This is a typical mistake of a novice and he probably initially ignored the advice of his JV partners, who have much more experience. Since customer service is a very critical aspect of sales generation and retention, McLaughlin should have produced a focused effort in-house where he could control its execution. You are correct to point out the decline in sales growth in month 3, but it was clearly due to poor customer service performance. The move in house, according to the company has already energized new sales and sales retention, reduced operating cots and will increase margins.
IMO the company is on the right track and I look forward to a resumption, even an acceleration of sales growth and in profitability in Q2. All in all, a good developmental quarter for IMMD!
Looks like market makers moving it back down so they can get some cheaper shares. Those who sold today on the down will regret. Just one nice announcement and the crossover will occur. Then high $.40's.
Great chart. A nice P.R., bringing intensified demand and we're off to $.49
I agree. But this CEO absolutely sucks at keeping shareholders informed.
I was correct. IMMD hit $.395 and has since backed off. Not to worry. Check the charts. This performance is similar to the behavior throughout this upswing. Hit new recent high, then pull back a bit and resume slog to another recent new high. Due to double top at $.40 it may take a few attempts to break through. With a decent announcement about positive sales trends or another new marketing channel development it will happen sooner rather than later.
$.40 may be a challenge. We have a double top around that level in the last 3 years. But is IMMD gets through that level....."to the moon Alice!"
Only 30,000 shares and $12,000 to $.58. A good announcement on revenue run rate gets us there.
Results? What results? They didn't publish Q1 revenues! Why not?
"Could" is speculative and based on a certain performance that has not occurred. While this new situation holds promise, nothing has happened yet in terms of EXECUTION. They have not even released Q1 revenues. Why?
I take issue with your characterization of my truthful and reasonable comments as rants. Also I bear no personal animus to the CEO. I am truthful in my assessment of his tenure as CEO regarding his several marketing mistakes. You ARE an apologist because you simply will not recognize the truth. Foolish shareholders like you simply enable greedy CEO's to take advantage of shareholders. Sweeping the facts under the rug does no good for the company only promotes poor corporate governance.
You have a simple view. What if sales trailed off in March? Two months does not make a trend nor a success. They have not restrained the level of shares. Extending warrants amounts to increasing fully diluted shares. Also check out how many options are outstanding. Through such awards, company insiders take the company away from shareholders. It appears that you want a success so badly that you overlook important info., or you are a friend of McLaughlin and an apologist for him. The fact remains that he has done only a barely mediocre job thus far, and a poor job until most recently with marketing decisions, AND the jury is still out on his latest decision. That is precisely why he should immediately release Q1 revenues in order to add credence to the company's performance.
Just 33,000 shares or $12,000 to reach $.50. See L2. Need some info on Q1 revenues as promised.
We do not KNOW that Q1 was a success. They released revenues for Jan and feb only. Do you know that March didn't fall off the cliff? Or did sales accelerate in March? No you don't know and that is why the s/p has drifted down. No info as promised by the company. Patience? As I posted before it takes very little time and effort to pull off a sales journal. While I understand that you do not want to see any negative posts about the company, truth is important. McLaughlin has been a mediocre CEO at best and has excessively enriched himself at the expense of the company and shareholders. What makes IMMD such an extraordinary investment is the patent protected processes that produce by far the most pure beta glucan available, not the CEO.
Level 2 today....40,000 shares, just $12,000 takes us up to $.39. Yet McLaughlin delays announcemment on 1Q revenues. Many of us have run companies or done accounting. It is not a big deal to print out a sales journal just a few days after close of month. It seems that McLoser is tone deaf when it comes to shareholders, BUT he is great at giving himself raises and getting his crony board to extend his own warrants.
Looking at Level 2, it seems that less than $25,000 in buying would take IMMD right up to $.40. One decent announcement on revenues does it.
Comments: The company made a great deal of progress in recovering from the Marketing V.P. debacle that McLaughlin entered into. They seem poised to grow and benefit from increased sales. Feels like they are a real nutriceutical company. Look forward to seeing sales and run rate for 1Q.
Comments: on 10K and notes: Notice that Mclaughlin's warrants that expired were EXTENDED by the board. Well, for those of you who participated in one of IMMD'S private placements, did you have your warrants extended? Of course we didn't. This is an example os self-dealing and rubber stamping by a board. What comes to mind? GREED? SCUMBAG? CRONYISM?
My first inclination was to agree with you totally. This is a lot of money and a lot of stock for one year of IR services. However, I know Mark and I know he is very conservative in spending corporate resources and I also know he has been very cautious in issuing stock and has protected the company's capital structure. Hence, I think we must reserve judgement until we see how things play out. Since November there is no evidence that this IR group is a pump and dump operation which is often associated with other pink sheet companies. To the contrary what we have observed is a very steady exposure of the company to new investors. I even thought I detected a real effort to control the increase in s/p over the last month so that perhaps some friends could get in at more reasonable prices (Note today that the bid/ask has precipitously dropped from 28-29 to 24-25 where it is right now. Looks like intentional manipulation.) IMO there will be a lot more info and a lot more buying soon AND an uplisting to a better exchange that will enhance price movement, and that may be one of the tasks of the new IR group.
Nice find. Price target is indeed reasonable.
This chart is flashing a big move up. Ditto recent behavior with volume and price moving up nicely. All happening without info coming out. IMO people in the JV partner's network and new end users may be responsible for the move up, which is very exciting for us L-T holders. When last Q and Jan and feb sales info is released IMMD will take off.
From the view of the charts, it is happening. Just a matter of a few days at most. Not a lot for sale, so even on moderate volume it moves. Just think what will happen with a decent P.R. This company moves despite poor investor relations.
The IMMD charts portend an intense upward trend starting. MacD crossover, exceeding 50 day and 200 day MA on both charts. Volume slowly and steadily building. Further, there is very little for sale. IMMD is ready to move, even surge with any significant volume.
This is a wonderfully composed investor update. The contents present not only a company that IS executing on a new marketing program, but also lining up subsequent new product opportunities through focused research and line extensions. Looks very very promising. Further, IMHO the projections and timelines are sure to be very conservative and I look for the company to exceed the presentation. If I know McLaughlin, the numbers are already materializing, what IMMD predicted is happening right now, and the timelines will be met and even superceded, because he will NOT allow himself to be embarrassed by a projection that is not achieved as in the case where he and the company were led astray by a non-performing new V.P. Marketing. It is happening!!!!!!!!!
I am pleased to finally see the announcement of the engagement of a financial P.R. firm to bring more eyeballs to IMMD. I guess that sales must be rising due to the new marketing initiative, and there is now positive cash flow to do that. I have looked into the firm and they are a reputable firm with extensive network that seems to know what they are doing. More than that, they are not a fly by night pumper and dumper. They provide a real service to their clients.
The new marketing channel partner is obviously a welcome development, and one that we have been pleading for for a very long time. Their type of internet based network marketing can be very effective and I look forward to an almost exponential type of growth that is possible with that operation.
IMMD still needs at least one more marketing channel -- large distributor capable of getting products into large chains, an MLM company, a very connected rep who can get large wholesale sales with major food and beverage producers. No reason why company cannot execute in tandem. Sequential execution is a poor and primitive marketing concept.
BEWARE! The CEO, Harp Sangha, is also CEO of VRCI. Its stock price went from $.80 to $.015. Same M.O. I see here -- issued sexy announcements, got the momentum going and sold into the buying, leaving an empty shell for the unsuspecting investors. ENVV has no $ and no prospects of getting an acquisition done except through raising capital, and based on the Ceo's record, that is unlikely.
A very positive announcement with strong potential upside. But, as is the case with the ineffective, incompetent and arrogant management of IMMD, there has been NO impact on the stock price. Crickets chirping! The reason: NO financial P.R. to bring new investors to IMMD. IMMD has been so quite for about 2 years since the debacle with Karen Kingston (which cost IMMD $350,000 and yielded NO revenues) that we need to drive new investors to the stock. The only ones who see a mere announcement are existing shareholders who are looking for news. But most existing shareholders have enough of the shares. McLoser, arrogant as ever, either thinks he knows better than the experts how to create interest or there is no money for financial P.R. because he and his wife take excessive salaries in their greedy self-enrichment, leaving no free cash flow to help build wealth for shareholders.$170,00/year for a company with $1.1 mm in revenues is greedy and excessive.
Shareholders should call McLoser (his phone number is on the website) and complain. Also call the board chair. Anthony Bruzzesse) and complain about the board's rubber stamping, ineffective leadership that enables McLoser to line his pockets as shareholders' interests are overlooked. Do they know anything about fiduciary responsibility?
Down again today.Your boy McLoser has lost you 72% of your original investment!
Just getting lots of satisfaction by pointing out how corrupt and incompetent you are. You shouldn't be so smug. Your investment is down 60%. Great move!
They are due for announcements.
IMMD shareholders and interested investors need to read this article. Projects massive growth in beta glucan market from 2015 to 2020.
Yeast Extract and Beta Glucan Market - Global Industry Analysis, Size, Share, Growth and Forecast 2015 - 2021 - Pr
Also:
https://uk.finance.yahoo.com/news/research-markets-beta-glucan-market-122500938.html
The big question is whether the incompetent and arrogant CEO, Mark McLoser will be able to take advantage of it. To date he has burned $550,000 on 2 failed marketing efforts and apparently he is now gun-shy because no new marketing initiatives have been announced since the last debacle. Maybe the company has no capital for a marketing budget since McLoser and his wife extract the entire profit of IMMD in their exorbitant money grab of $14,000 per month. That's almost $170,000 per year from a break-even company. Obviously McLoser cares more about himself than the shareholders. Self-dealing! Call McLoser and demand that he cut his salary extinguish most of his options and hire a competent marketing/CEO. While you are at it, deluge the rubber stamp board members to stop going along and assume the fiduciary responsibility to the shareholders.
Well, the month of June has come and gone and IMMD shareholders saw their investment decline by 10%. For the last 6 months, our investment has declined by 35%. During those periods of time, McLaughlin and his wife were paid $14,500 and $87,000, respectively. There were no announcements regarding significant marketing and sales strides, such as relationships with distributors, chain stores,internet marketers, large wholesale accounts, etc. When will McLaughlin wake up and realize that he does not possess the marketing savvy to launch IMMD's world class products and leverage IMMD's significant patents? McLaughlin should cut his compensation in half, including his options, and bring in the marketing pros who can produce returns for IMMD's shareholders. Unfortunately, McLaughlin's past actions do not bode well for such an altruistic move. Remember, over the last 5 or 6 years as IMMD's shareholders saw their investment decline by more than 50%, McLaughlin increased his salary by 45% and awarded himself millions of options, all rubber stamped by a go along, ineffectual board. But if the incompetent and arrogant McLaughlin will not act altruistically for the benefit of the shareholders, maybe he will make the moves for his own benefit, since he is IMMD's largest shareholder. Wake up and let someone with proven competence market IMMD's exceptional products and enrich us all!
Today's precipitous drop in price has nothing to do with the intrinsic value of IMMD and its products and patents, nor with its potential. It has everything to do with an uninformed shareholder who executed a market sell order on a penny stock and got clobbered, and a company with no financial P.R. program, no uplifting announcements and no one at the helm capable of developing a relationship with a significant nutriceutical distributor who can get IMMD's products into the chain stores. McLaughlin, who fits the definition of incompetent as it pertains to marketing, should cut his compensation package in half, bring on an experienced industry person who can get deals going with one or more large distributors, and hire a reliable financial public relations firm to bring new investors to IMMD. Will he?
Personal attack again. Are you so bereft of an intelligent response that you have to make such childish posts? You should be barred from the message board. Do your job MrGoodtrade and bounce this imglict off the board.
From Webster's...
INCOMPETENT 1)inadequate to or unsuitable for a particular purpose 2)lacking the qualities needED for effective action 3) unable to function properly.
IMMD, with a world-class product, with proven efficacy and proven superiority in its space, has seen its stock price decline 60% during McLaughlin's tenure. He burned up $550,000 with 2 bad marketing decisions (Karen Kingston and John Burke) that brought in NO revenues. He has been unable to gain a relationship with a major nutriceutical distributor who can get the products into the major chains.
ARROGANT 1)exaggerating one's own worth in an overbearing manner.
During this time of losses for shareholders, McLaughlin has increased his salary by 45%, awarded himself millions of options and even gave options to his wife who merely does bookkeeping part-time for the company.
That sums up McLauglin's management of YOUR company over the last 5 years -- INCOMPETENT, ARROGANT!
You must be someone who is still irrational over the reverse split. You should probably try to get your losses back by buying right now. Time will tell if the team, the people are real or not. I do not believe that the people, the university and the pharma company named, all of whom can be Googled and proven to have the qualifications stated, would allow their names to be used inappropriately. You will probably continue to slam the CEO, but those of us who like what he has recently done will be rewarded!